Imaging Manifestations of Pseudoprogression in Metastatic Melanoma Nodes Injected with Talimogene Laherparepvec: Initial Experience

References

1. 1.↵
   2. Andtbacka RH,
   3. Kaufman HL,
   4. Collichio F, et al

   . Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 2015;33:2780–88 doi:10.1200/JCO.2014.58.3377 pmid:26014293

   Abstract/FREE Full Text
2. 2.↵
   2. Ott PA,
   3. Hodi FS

   . Talimogene laherparepvec for the treatment of advanced melanoma. Clin Cancer Res 2016;22:3127–31 doi:10.1158/1078-0432.CCR-15-2709 pmid:27146699

   Abstract/FREE Full Text
3. 3.↵
   2. Rehman H,
   3. Silk AW,
   4. Kane MP, et al

   . Into the clinic: talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. J Immunother Cancer 2016;4:53 doi:10.1186/s40425-016-0158-5 pmid:27660707

   CrossRefPubMed
4. 4.↵
   2. Hu JC,
   3. Coffin RS,
   4. Davis CJ, et al

   . A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006;12:6737–47 doi:10.1158/1078-0432.CCR-06-0759 pmid:17121894

   Abstract/FREE Full Text
5. 5.↵
   2. Appleton ES,
   3. Turnbull S,
   4. Ralph C, et al

   . Talimogene laherparepvec in the treatment of melanoma. Expert Opin Biol Ther 2015;15:1517–30 doi:10.1517/14712598.2015.1084280 pmid:26629575

   CrossRefPubMed
6. 6.↵
   2. Wolchok JD,
   3. Hoos A,
   4. O'Day S, et al

   . Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412–20 doi:10.1158/1078-0432.CCR-09-1624 pmid:19934295

   Abstract/FREE Full Text
7. 7.↵
   2. Fukuhara H,
   3. Ino Y,
   4. Todo T

   . Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci 2016;107:1373–79 doi:10.1111/cas.13027 pmid:27486853

   CrossRefPubMed
8. 8.↵
   2. Kaufman HL,
   3. Amatruda T,
   4. Reid T, et al

   . Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study. J Immunother Cancer 2016;4:12 doi:10.1186/s40425-016-0116-2 pmid:26981242

   CrossRefPubMed
9. 9.↵
   2. Kaufman HL,
   3. Kohlhapp FJ,
   4. Zloza A

   . Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 2015;14:642–62 doi:10.1038/nrd4663 pmid:26323545

   CrossRefPubMed
10. 10.↵
    2. Gray MR,
    3. Martin del Campo S,
    4. Zhang X, et al

    . Metastatic melanoma: lactate dehydrogenase levels and CT imaging findings of tumor devascularization allow accurate prediction of survival in patients treated with bevacizumab. Radiology 2014;270:425–34 doi:10.1148/radiol.13130776 pmid:24072776

    CrossRefPubMed
11. 11.↵
    2. Nishino M,
    3. Giobbie-Hurder A,
    4. Ramaiya NH, et al

    . Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome. J Immunother Cancer 2014;2:40 doi:10.1186/s40425-014-0040-2 pmid:25411640

    CrossRefPubMed
12. 12.↵
    2. Mermod M,
    3. Tolstonog G,
    4. Simon C, et al

    . Extracapsular spread in head and neck squamous cell carcinoma: a systematic review and meta-analysis. Oral Oncol 2016;62:60–71 doi:10.1016/j.oraloncology.2016.10.003 pmid:27865373

    CrossRefPubMed
13. 13.↵
    2. Maxwell JH,
    3. Ferris RL,
    4. Gooding W, et al

    . Extracapsular spread in head and neck carcinoma: impact of site and human papillomavirus status. Cancer 2013;119:3302–08 doi:10.1002/cncr.28169 pmid:23797868

    CrossRefPubMed
14. 14.↵
    2. Bibault JE,
    3. Dewas S,
    4. Mirabel X, et al

    . Adjuvant radiation therapy in metastatic lymph nodes from melanoma. Radiat Oncol 2011;6:12 doi:10.1186/1748-717X-6-12 pmid:21294913

    CrossRefPubMed
15. 15.↵
    2. Nathansohn N,
    3. Schachter J,
    4. Gutman H

    . Patterns of recurrence in patients with melanoma after radical lymph node dissection. Arch Surg 2005;140:1172–77 doi:10.1001/archsurg.140.12.1172 pmid:16365238

    CrossRefPubMedWeb of Science
16. 16.↵
    2. Brahmer JR,
    3. Tykodi SS,
    4. Chow LQ, et al

    . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455–65 doi:10.1056/NEJMoa1200694 pmid:22658128

    CrossRefPubMedWeb of Science
17. 17.↵
    2. van Baren N,
    3. Bonnet MC,
    4. Dréno B, et al

    . Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol 2005;23:9008–21 doi:10.1200/JCO.2005.08.375 pmid:16061912

    Abstract/FREE Full Text
18. 18.↵
    2. Saenger YM,
    3. Wolchok JD

    . The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Cancer Immun 2008;8:1 pmid:18198818

    Abstract/FREE Full Text
19. 19.↵
    2. Chiou VL,
    3. Burotto M

    . Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 2015;33:3541–43 doi:10.1200/JCO.2015.61.6870 pmid:26261262

    FREE Full Text
20. 20.↵
    2. Covington MF,
    3. Curiel CN,
    4. Lattimore L, et al

    . FDG-PET/CT for monitoring response of melanoma to the novel oncolytic viral therapy talimogene laherparepvec. Clin Nucl Med 2017;42:114–15 doi:10.1097/RLU.0000000000001456 pmid:27922859

    CrossRefPubMed
21. 21.↵
    2. Koski A,
    3. Ahtinen H,
    4. Liljenback H, et al

    . [(18)F]-fluorodeoxyglucose positron emission tomography and computed tomography in response evaluation of oncolytic adenovirus treatments of patients with advanced cancer. Hum Gene Ther 2013;24:1029–41 doi:10.1089/hum.2013.123 pmid:24099555

    CrossRefPubMed